HOXB9 and cancer: The HOXB9 OE/SKOV3-injected group was heavier than the SKOV3-injected group after four weeks of cancer cell injection before cisplatin treatment (Figure 4B, 23.1 mg ± 0.9 mg vs. 21.3 mg ± 0.7 mg; p = 0.004).